Endometriose: medikamentöse Rezidivprophylaxe nach Laparoskopie

Judith Lorenz
In: Geburtshilfe und Frauenheilkunde · 2023 · vol. 83(10) , pp. 1162–1163 · doi:10.1055/a-2130-6045 · W4387407161
RCT OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-24 ⓘ

A randomized controlled trial from Iran evaluated the efficacy of dienogest and medroxyprogesterone acetate in preventing endometriosis recurrence and alleviating clinical symptoms following laparoscopic surgery.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-15 · read from full text ⓘ

This article reviews a randomized controlled trial conducted in Iran to evaluate the efficacy of Dienogest and Medroxyprogesterone acetate (MPA) as medical prophylaxis against endometriosis recurrence following laparoscopic surgery. The study specifically aimed to determine how well these two progestins prevent the development of new endometrial lesions and alleviate associated clinical symptoms in women who have undergone surgical intervention. The text highlights that a significant proportion of patients experience lesion recurrence after surgery, prompting the investigation into these pharmacological options for maintaining long-term symptom control and preventing disease progression. This paper is centrally about endometriosis — specifically the use of hormonal therapies for preventing disease recurrence after laparoscopic excision.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Ein erheblicher Anteil der Frauen, die sich aufgrund einer Endometriose einem laparoskopischen chirurgischen Eingriff unterziehen, entwickelt im Verlauf erneut Endometrioseläsionen. Wie gut schützen Dienogest und Medroxyprogesteronacetat (MPA) vor solchen Rezidiven? Und wie gut lindern die beiden Wirkstoffe die klinischen Symptome? Diesen Fragen ging eine randomisierte kontrollierte Studie aus dem Iran nach.
Full text 923 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS Please copy the URL and add it into your RSS Feed Reader. https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml Geburtshilfe Frauenheilkd 2023; 83(10): 1162-1163 DOI: 10.1055/a-2130-6045 DOI: 10.1055/a-2130-6045 GebFra Magazin Aktuell referiert Endometriose: medikamentöse Rezidivprophylaxe nach Laparoskopie Authors Ein erheblicher Anteil der Frauen, die sich aufgrund einer Endometriose einem laparoskopischen chirurgischen Eingriff unterziehen, entwickelt im Verlauf erneut Endometrioseläsionen. Wie gut schützen Dienogest und Medroxyprogesteronacetat (MPA) vor solchen Rezidiven? Und wie gut lindern die beiden Wirkstoffe die klinischen Symptome? Diesen Fragen ging eine randomisierte kontrollierte Studie aus dem Iran nach. Publication History Article published online: 05 October 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

die_deep_infiltrating

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK